Document is current
Any future updates will be listed below
-
Authors
Kamigaichi, Atsushi
Kagamu, Hiroshi
Miyata, Yoshihiro
Mimae, Takahiro
Tsubokawa, Norifumi
Hirano, Koichi
Okada, Morihito
-
Funding
Funding for this research was provided by:
Hiroshima University
- License Information
-
More Information
Article History
Received: 31 January 2026
Accepted: 27 February 2026
First Online: 28 April 2026
Declarations
:
: H. Kagamu reports personal fees from Bristol Myers Squibb, MSD, AstraZeneca, Ono Pharmaceutical, Amgen, and Janssen; grants from Boehringer Ingelheim; and stock ownership in ImmuniT Research Inc. outside the submitted work. T. Mimae reports personal fees from MSD and Chugai Pharmaceutical outside the submitted work. M. Okada reports personal fees from MSD, Ethicon, Covidien, Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca, and Bristol Myers Squibb outside the submitted work. No disclosures were reported by the other authors.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Hiroshima University Hospital (approval date: May 30, 2023; approval code: E-2022–0278).
: Written informed consent was obtained from each participant.
